A detailed history of Exodus Point Capital Management, LP transactions in Xencor Inc stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 173,969 shares of XNCR stock, worth $3.18 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
173,969
Previous 294,938 41.02%
Holding current value
$3.18 Million
Previous $5.94 Million 35.22%
% of portfolio
0.03%
Previous 0.06%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$18.65 - $26.52 $2.26 Million - $3.21 Million
-120,969 Reduced 41.02%
173,969 $3.85 Million
Q3 2023

Nov 09, 2023

BUY
$20.08 - $25.39 $3.11 Million - $3.93 Million
154,826 Added 110.5%
294,938 $5.94 Million
Q2 2023

Aug 10, 2023

BUY
$24.77 - $29.9 $614,717 - $742,028
24,817 Added 21.52%
140,112 $3.5 Million
Q1 2023

May 11, 2023

BUY
$25.95 - $36.95 $2.99 Million - $4.26 Million
115,295 New
115,295 $3.22 Million
Q3 2022

Nov 10, 2022

SELL
$24.62 - $32.44 $363,465 - $478,911
-14,763 Closed
0 $0
Q2 2022

Aug 19, 2022

BUY
$19.74 - $29.01 $291,421 - $428,274
14,763 New
14,763 $404,000
Q1 2022

May 13, 2022

SELL
$26.68 - $41.63 $663,318 - $1.04 Million
-24,862 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$33.67 - $43.44 $837,103 - $1.08 Million
24,862 New
24,862 $997,000
Q3 2021

Nov 15, 2021

SELL
$30.65 - $35.68 $485,465 - $565,135
-15,839 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$34.33 - $44.68 $543,752 - $707,686
15,839 New
15,839 $546,000
Q4 2020

Feb 16, 2021

SELL
$36.63 - $47.63 $248,571 - $323,217
-6,786 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$30.09 - $43.02 $204,190 - $291,933
6,786 New
6,786 $263,000
Q1 2020

May 15, 2020

SELL
$20.69 - $37.79 $124,740 - $227,835
-6,029 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$32.75 - $41.43 $197,449 - $249,781
6,029 New
6,029 $207,000

Others Institutions Holding XNCR

About Xencor Inc


  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.09B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.